forbes glp 1 reviews GLP-1 medicines entered clinical use in 2005 as treatments for Type 2 diabetes. Over time, doctors observed their effects on appetite and body weight, leading to separate approvals for obesity treatment. In How GLP-1 Weight Loss Drugs

Serious hypersensitivity reactions such as anaphylaxis and angioedema have occurred with these drugs

Its worth noting that comparing results across weight loss trials can be difficult, since studies often include different patient populations, treatment durations, dosing schedules, and study methods

Eli Lilly launched Mounjaro in India in March 2025, followed by Novo Nordisks Wegovy in June 2025

10.1146/annurev-animal-111523-102249 Annu Rev Anim Biosci

Particularly for those who are trying to conceive, pregnant and postpartum

Recalls & Warnings September 15, 2013 Creatine Powder Containing DMAA Recalled On September 12, 2013, Ge Pharma, LLC issued a recall of grape and fruit punch flavors of Creafuse Powder because they contain 1,3 dimethylamylamine (DMAA)